Therapy and prophylaxis of systemic protozoan infections.
This article summarises current therapy and prophylaxis for Pneumocystis carinii, Toxoplasma gondii, Leishmania species, African trypanosomes (Trypanosoma brucei gambiense and T. b. rhodesiense), and American trypanosome (Trypanosoma cruzi) infections. Each agent and the disease it causes is briefly reviewed, and current data on the structure, mode of action, indications for treatment, dosage, administration, duration of therapy, efficacy, toxicity, and necessary monitoring during therapy are discussed for each drug. Drugs considered include cotrimoxazole (trimethoprim + sulfamethoxazole), pentamidine, dapsone (diaphenylsulfone), trimetrexate, eflornithine (DFMO), and primaquine/clindamycin and pyrimethamine/sulphonamide combinations for Pneumocystis pneumonia; pyrimethamine/sulfadiazine, spiramycin, and clindamycin for toxoplasmosis; pentavalent antimonials ('Pentostam' and 'Glucantime'), pentamidine, amphotericin B, allopurinol, ketoconazole, and itraconazole for leishmaniasis; suramin, pentamidine, melarsoprol, tryparsamide, Mel W, berenil, and eflornithine (DFMO) for African trypanosomiasis; and nifurtimox, benznidazole and gentian violet for American trypanosomiasis.
Van Voorhis
W C
WC
Tropical Medicine Clinic, University of Washington Medical School, Seattle.
D014355:Chagas Disease / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D007896:Leishmaniasis / Q000188:drug therapy / Q000517:prevention & control; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy / Q000517:prevention & control; D011528:Protozoan Infections / Q000188:drug therapy*; D014123:Toxoplasmosis / Q000188:drug therapy / Q000517:prevention & control; D014353:Trypanosomiasis, African / Q000188:drug therapy / Q000517:prevention & control